AnGes
As of the edition of 20 October 2026, AnGes runs 4 drugs, 1 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Lonafarnib | Ends 2027 (exclusivity) | 3 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| FNTB Protein farnesyltransferase subunit beta | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where AnGes needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Infections: 3 trials led
- Lungs and airways: 3 trials led
- Heart and blood vessels: 2 trials led